ATE494008T1 - Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen - Google Patents
Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungenInfo
- Publication number
- ATE494008T1 ATE494008T1 AT07730142T AT07730142T ATE494008T1 AT E494008 T1 ATE494008 T1 AT E494008T1 AT 07730142 T AT07730142 T AT 07730142T AT 07730142 T AT07730142 T AT 07730142T AT E494008 T1 ATE494008 T1 AT E494008T1
- Authority
- AT
- Austria
- Prior art keywords
- kinase inhibitor
- psychiatric diseases
- treat psychiatric
- treat
- diseases
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 208000020016 psychiatric disease Diseases 0.000 title abstract 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0612026.5A GB0612026D0 (en) | 2006-06-16 | 2006-06-16 | New use |
| PCT/EP2007/055858 WO2007144390A1 (en) | 2006-06-16 | 2007-06-13 | Use of a p38 kinase inhibitor for treating psychiatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE494008T1 true ATE494008T1 (de) | 2011-01-15 |
Family
ID=36775828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07730142T ATE494008T1 (de) | 2006-06-16 | 2007-06-13 | Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7989479B2 (de) |
| EP (1) | EP2029139B1 (de) |
| JP (1) | JP2010528980A (de) |
| KR (1) | KR20090020703A (de) |
| CN (1) | CN101500567B (de) |
| AT (1) | ATE494008T1 (de) |
| AU (1) | AU2007259224A1 (de) |
| CA (1) | CA2657390A1 (de) |
| DE (1) | DE602007011756D1 (de) |
| EA (1) | EA015483B1 (de) |
| ES (1) | ES2358931T3 (de) |
| GB (1) | GB0612026D0 (de) |
| WO (1) | WO2007144390A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4472349B2 (ja) * | 2002-02-12 | 2010-06-02 | スミスクライン ビーチャム コーポレーション | ｐ３８阻害薬として有用なニコチンアミド誘導体 |
| CN102633715B (zh) * | 2012-03-23 | 2014-03-26 | 无锡爱内特营养保健品科技有限公司 | 一种丝裂原蛋白激酶p38的抑制剂及其制备方法 |
| CN105358148A (zh) * | 2013-07-10 | 2016-02-24 | 葛兰素史克知识产权第二有限公司 | 用于治疗肾小球疾病的losmapimod |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| JP2021501130A (ja) | 2017-10-05 | 2021-01-14 | フルクラム セラピューティクス，インコーポレイテッド | ＤＵＸ４の発現を低減するためのｐ３８阻害剤の使用 |
| WO2019103926A1 (en) * | 2017-11-21 | 2019-05-31 | Saint Louis University | P38 inhibitors for the treatment of fshd |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003503456A (ja) * | 1999-07-02 | 2003-01-28 | スチュアート エイ． リプトン | 神経傷害またはアポトーシスを軽減する方法 |
| GB0124931D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124932D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124936D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124939D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124933D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124934D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124938D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| JP4472349B2 (ja) | 2002-02-12 | 2010-06-02 | スミスクライン ビーチャム コーポレーション | ｐ３８阻害薬として有用なニコチンアミド誘導体 |
| GB0209891D0 (en) | 2002-04-30 | 2002-06-05 | Glaxo Group Ltd | Novel compounds |
| CA2484631A1 (en) | 2002-05-13 | 2003-11-27 | Merck & Co., Inc. | Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles |
| GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| GB0308201D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308185D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308186D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0318814D0 (en) | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
| GB0402140D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| GB0402138D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| WO2006009114A1 (ja) * | 2004-07-16 | 2006-01-26 | Atsuo Sekiyama | Ｉｌ－１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物 |
| US20080051416A1 (en) | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
| GB0512429D0 (en) | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
| EP2034838A4 (de) | 2006-06-16 | 2012-01-04 | Glaxo Group Ltd | Neuartige verbindungen |
| EP2031965A4 (de) | 2006-06-16 | 2010-06-30 | Glaxo Group Ltd | Neuartige verbindungen |
| US20090318424A1 (en) | 2006-06-16 | 2009-12-24 | Mauro Corsi | Novel compounds |
-
2006
- 2006-06-16 GB GBGB0612026.5A patent/GB0612026D0/en not_active Ceased
-
2007
- 2007-06-13 CA CA002657390A patent/CA2657390A1/en not_active Abandoned
- 2007-06-13 DE DE602007011756T patent/DE602007011756D1/de active Active
- 2007-06-13 EP EP07730142A patent/EP2029139B1/de active Active
- 2007-06-13 EA EA200900034A patent/EA015483B1/ru not_active IP Right Cessation
- 2007-06-13 KR KR1020097000928A patent/KR20090020703A/ko not_active Withdrawn
- 2007-06-13 CN CN2007800290002A patent/CN101500567B/zh not_active Expired - Fee Related
- 2007-06-13 AU AU2007259224A patent/AU2007259224A1/en not_active Abandoned
- 2007-06-13 JP JP2009514798A patent/JP2010528980A/ja active Pending
- 2007-06-13 AT AT07730142T patent/ATE494008T1/de not_active IP Right Cessation
- 2007-06-13 US US12/305,045 patent/US7989479B2/en not_active Expired - Fee Related
- 2007-06-13 WO PCT/EP2007/055858 patent/WO2007144390A1/en not_active Ceased
- 2007-06-13 ES ES07730142T patent/ES2358931T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007144390A1 (en) | 2007-12-21 |
| CN101500567B (zh) | 2012-05-16 |
| EA200900034A1 (ru) | 2009-06-30 |
| EP2029139A1 (de) | 2009-03-04 |
| DE602007011756D1 (de) | 2011-02-17 |
| KR20090020703A (ko) | 2009-02-26 |
| CN101500567A (zh) | 2009-08-05 |
| US7989479B2 (en) | 2011-08-02 |
| US20100016377A1 (en) | 2010-01-21 |
| ES2358931T3 (es) | 2011-05-16 |
| GB0612026D0 (en) | 2006-07-26 |
| EP2029139B1 (de) | 2011-01-05 |
| EA015483B1 (ru) | 2011-08-30 |
| CA2657390A1 (en) | 2007-12-21 |
| JP2010528980A (ja) | 2010-08-26 |
| AU2007259224A1 (en) | 2007-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006195A (es) | Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso. | |
| ATE416177T1 (de) | Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| ATE406351T1 (de) | Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren | |
| ATE517896T1 (de) | P38-kinase-inhibitoren | |
| CY1112238T1 (el) | Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων | |
| CY1109985T1 (el) | Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων | |
| GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| UA92503C2 (ru) | Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств | |
| ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
| MY148851A (en) | Dihydropyridine derivatives as useful as protein kinase inhibitors | |
| NO20082508L (no) | Aminopyrimidiner anvendelige som kinaseinhibitorer | |
| DE602006004844D1 (de) | Pyrrolopyrimidine verwendbar als protein kinase inhibitoren | |
| CY1108230T1 (el) | Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri | |
| TW200634012A (en) | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | |
| ATE521608T1 (de) | Glucokinaseaktivatoren | |
| ATE438404T1 (de) | Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien | |
| NO20071378L (no) | Tiazolo-naftylsyrer. | |
| BRPI0517435A (pt) | triazóis úteis como inibidores de proteìna cinase | |
| PH12012502070A1 (en) | Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders | |
| ATE494008T1 (de) | Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen | |
| ATE542536T1 (de) | 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen | |
| ATE441632T1 (de) | Gesättigte und ungesättigte 3-pyridyl- benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen | |
| EA200701995A1 (ru) | Способы уменьшения кальцификации | |
| ATE424208T1 (de) | Proteinkinaseinhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |